Tag: Avelumab
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcino

European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcino

Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with ...

Lees verder
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019

New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019

Not intended for US, Canada and UK-based media DARMSTADT, Germany, and NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Merck and Pfizer Inc. today announced the presentation of ...

Lees verder
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of

Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of

Not intended for US, Canada and UK-based media DARMSTADT, Germany and NEW YORK, Feb. 16, 2019 /PRNewswire/ -- -- JAVELIN Renal 101 shows significant improvement in ...

Lees verder
Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany and NEW YORK, December 21, 2018 /PRNewswire/ -- Not intended for US, Canada and UK-based media   Merck and Pfizer Inc. today announced that data from a ...

Lees verder
Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

DARMSTADT, Germany and NEW YORK, November 19, 2018 /PRNewswire/ -- Not intended for US, Canada and UK-based media  Merck and Pfizer Inc. today announced that the Phase III ...

Lees verder
Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Smal

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Smal

DARMSTADT, Germany and NEW YORK, February 15, 2018 /PRNewswire/ -- Not intended for UK-based media Merck and Pfizer Inc. today announced results from the Phase III JAVELIN ...

Lees verder
FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

DARMSTADT, Germany and NEW YORK, December 21, 2017 /PRNewswire/ -- - Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer  - Renal ...

Lees verder
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

DARMSTADT, Germany, and NEW YORK, USA, September 21, 2017 /PRNewswire/ -- Not intended for US, Canadian and UK-based media     - First approved immunotherapy for ...

Lees verder
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

DARMSTADT, Germany and NEW YORK, July 21, 2017 /PRNewswire/ -- Not intended for US, Canadian and UK-based media   - If approved, ...

Lees verder
BizPress.nl